Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Breast cancer

Jumonji domain containing 2C
(JMJD2C; KDM4C)

Cell culture, mouse and patient sample studies suggest inhibiting JMJD2C could help treat breast cancer. In a human cancer cell line, JMJD2C bound to and functioned as a coactivator of hypoxia-inducible factor 1a (HIF1A; HIF1a), a known driver of breast cancer metastasis. In a xenograft mouse model of breast cancer, small hairpin RNA against JMJD2C decreased tumor growth and metastasis compared with control shRNA. In patient breast tissue samples, JMJD2C expression was greater in carcinoma samples than in normal tissue and correlated with higher tumor grade. Next steps could include testing small molecule JMJD2C inhibitors in cancer cell lines.

SciBX 5(45); doi:10.1038/scibx.2012.1178
Published online Nov. 15, 2012

Patent and licensing status undisclosed

Luo, W. et al. Proc. Natl. Acad. Sci. USA; published online
Nov. 5, 2012;
doi:10.1073/pnas.1217394109
Contact: Gregg L. Semenza,
The Johns Hopkins University School of Medicine, Baltimore, Md.
e-mail:

gsemenza@jhmi.edu